Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Glatiramer→

Glatiramer Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
147245-92-9
Molecular formula
[C9H11NO2 . C6H13NO2 . C5H9NO4 . C3H7NO2]x
Molecular weight
~5000 to ~9000 g/mol
Drug class
Synthetic polypeptide immunomodulatormultiple sclerosis disease-modifying therapy
Mechanism of action
The mechanisms of action are not fully understood. Glatiramer acetate is thought to modulate immune responses, including effects on antigen-presenting cells and T-cell populations, shifting responses toward anti-inflammatory phenotypes and potentially reducing CNS-directed inflammatory activity.
Indications / reported uses
  • Treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease, under the applicable product label

Sources: US DailyMed — Glatiramer acetate · NLM MeSH — Glatiramer acetate · FDA product information

View request basketPrefer email? [email protected]
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Synthetic polypeptide immunomodulator; multiple sclerosis disease-modifying therapy

Mechanism of action

The mechanisms of action are not fully understood. Glatiramer acetate is thought to modulate immune responses, including effects on antigen-presenting cells and T-cell populations, shifting responses toward anti-inflammatory phenotypes and potentially reducing CNS-directed inflammatory activity.

General use cases

  • Treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease, under the applicable product label

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

ERA assessment scope

Project-specific environmental risk assessment support

The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.

  • Phase I exposure screening and trigger evaluation.
  • Environmental fate and ecotoxicity review, with Phase II work where required.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
  • Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope

Environmental Risk Assessment (ERA)

ReguSight provides project-specific support for the Glatiramer Environmental Risk Assessment (ERA) (the Glatiramer ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.